PDCD1 and acute myeloid leukemia: For example, early studies evaluating immune checkpoint inhibitors targeting PD-1/PD-L1 pathways, such as nivolumab or pembrolizumab, have not demonstrated consistent improvements in overall survival when used as monotherapy or in combination with chemotherapy in AML patients [90,91].